

**IN THE CLAIMS**

1. (Original) Highly active glycoprotein produced by a process comprising:

expression of said highly active glycoprotein in an expression cell line, harboring at least one defect in the sugar nucleotide biosynthetic pathway of sialic acids and which is transfected with nucleic acid encoding the glycoprotein, in a medium supplemented with a concentration of at least one sialic acid precursor additive, the concentration being determined by a process comprising:

(i) expression of a plurality of different sialylation forms of said glycoprotein by differential sialylation using different concentrations of at least one sialic acid precursor;

and

(ii) determination of the activity of the different sialylation forms in comparison with a reference glycoprotein in (a) suitable bioassay(s);

and

(ii) selection of the sialylation form with the higher/highest activity and determination of the concentration of the sialic acid precursor additive(s) which is correlated with the higher/highest activity level of said glycoprotein.

2. (Original) A glycoprotein according to claims 1, wherein the glycoprotein is secreted by the cells of the expression cell line.

3. (Previously Amended) A glycoprotein according to claim 1, wherein only one sialylation form is expressed in step (i).

4. (Previously Amended) A glycoprotein according to claim 1, wherein the higher activity of the glycoprotein is characterized by a higher activity in at least one in vitro model and/or a higher activity in at least one in vivo model and/or a higher stability and/or a longer serum-half life and/or a longer bioavailability and/or an improved immunogenicity and/or an improved antigenicity determined by at least one bioassay.

5. (Previously Amended) A glycoprotein according to claim 1, wherein the defect in the biosynthetic pathway of sialic acid is a mutation of an epimerase.

6. (Previously Amended) A glycoprotein according to claim 1, wherein the expression cell line is NM-F9 or NM-D4.
7. (Previously Amended) A glycoprotein according to claim 1, wherein the glycoprotein is selected from the group comprising Glycophorin A, EPO, G-CSF, GM-CSF, FSH, hCG, LH, interferons, interleukins, antibodies and/or fragments thereof.
8. (Previously Amended) A glycoprotein according to claim 1, wherein at least one sialic acid precursor additive is ManNAc, acetylated ManNAc, peracetylated ManNAc or fetuin.
9. (Previously Amended) Process for the production of a highly active glycoprotein according to claim 1, comprising:  
expression of said highly active glycoprotein in an expression cell line, harboring at least one defect in the sugar nucleotide biosynthetic pathway of sialic acids and which is transfected with nucleic acid encoding the glycoprotein, in a medium supplemented with a concentration of at least one sialic acid precursor additive, the concentration being determined by a process comprising:
  - (i) expression of a plurality of different sialylation forms of said glycoprotein by differential sialylation using different concentrations of at least one sialic acid precursor;  
and
  - (ii) determination of the activity of the different sialylation forms in comparison with a reference glycoprotein in (a) suitable bioassay(s);  
and
  - (iii) selection of the sialylation form with the higher/highest activity and determination of the concentration of the sialic acid precursor additive(s) which is correlated with the higher/highest activity level of said glycoprotein.
10. (Currently Amended) Process for the identification/determination of a highly active glycoprotein according to produced by the process of claim 1, comprising:

- i) transfection of expression cell line harboring at least one defect in the sugar nucleotide biosynthetic pathway of sialic acids with nucleic acid encoding the glycoprotein;  
and
- ii) expression of a plurality of different sialylation forms of said glycoprotein by differential sialylation using medium with different concentrations of at least one sialic acid precursor additive;  
and
- iii) determination of the activity of the different sialylation forms in comparison with a reference glycoprotein in (a) suitable bioassay(s);  
and
- iv) selection of the sialylation form with the higher/highest activity.

11. (Currently Amended) Process for differential sialylation of a glycoprotein according to ~~produced by the process of claim 1~~, characterized in that, a plurality of different sialylation forms of said glycoprotein are expressed in an expression cell line, harboring at least one defect in the sugar nucleotide biosynthetic pathway of sialic acids and which is transfected with nucleic acid encoding the glycoprotein, by using medium with different concentrations of at least one sialic acid precursor additive.

12. (Withdrawn) Process for the generation of an expression cell line with a defect in the sugar nucleotide biosynthetic pathway of sialic acids comprising the selection of expression cell line from primary cells or cell lines with a recognition molecule that binds to desialylated structures which can be sialylated by at least two enzymes.

13. (Withdrawn) Process of claim 12, wherein the cells from primary cells or cell lines are mutagenized before selection.

14. (Withdrawn) Process of claim 12, wherein the structures are O-glycans.

15. (Withdrawn) Process according to claims 12, wherein the desialylated structures can be sialylated by alpha2-3 and alpha2-6 bound sialic acids.

16. (Withdrawn) Process according to claim 12, wherein the recognition molecule is a lectin or a carbohydrate specific antibody.

17. (Withdrawn) Process according to claims 12, wherein the recognition molecule is a lectin or a carbohydrate specific antibody recognizing the core-1 structure.
18. (Withdrawn) Process according to claim 12, wherein the expression cell line is derived from the group comprising Per.C6, HEK293, K562, CV1, COS-7, Hybridoma cells, Namalwa, BHK and CHO.
19. (Currently Amended) Composition for *in vitro* and *in vivo* use, comprising a glycoprotein according to claims 1, and a diluent or carrier.
20. (Currently Amended) Pharmaceutical composition for use in therapy, comprising a glycoprotein according to claims 1, and a pharmaceutically-acceptable diluent or carrier.
21. (Original) Pharmaceutical composition according to claim 20, characterized in that, the composition is a vaccine or vaccine-adjuvant.
22. Canceled.
23. Canceled.